Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors?
Roivant Sciences (ROIV) recently reported a swing to profitability in Q4 2026, driven by one-off items, despite a full-year sales decline. This unexpected profit, coupled with advancements in its autoimmune pipeline, particularly brepocitinib, is reshaping its investment narrative. Investors should focus on regulatory outcomes and launch execution for its pipeline assets rather than the singular profitable quarter, as significant execution risks remain in its multi-trial autoimmune portfolio.
Roivant Sciences Is Maintained at Buy by Citigroup
Citigroup has reiterated its Buy rating on Roivant Sciences, indicating continued confidence in the company's stock. This maintenance of a positive rating by a major financial institution suggests a favorable outlook for Roivant Sciences in the near future.
ROIV Maintained by Citigroup -- Price Target Raised to $42.00
Citigroup has maintained a 'Buy' rating for Roivant Sciences (ROIV) and increased its price target from $35.00 to $42.00, reflecting increased confidence in the company's growth potential within the biotechnology sector. Despite this positive analyst sentiment, GuruFocus assesses ROIV as significantly overvalued with a GF Value™ of $7.07 against its current price of $31.58, and notes considerable insider selling activity totaling $105.6 million over the last three months. The company's GF Score™ of 43 out of 100 highlights below-average performance potential, particularly concerning its profitability and valuation metrics.
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $34 to $42
This article provides a quick overview of current analyst ratings for Roivant Sciences (ROIV.US). Analysts have set price targets for the company ranging from $34 to $42, indicating a positive outlook. This information is intended for potential investors tracking analyst sentiments and price forecasts.
Leerink raises Roivant Sciences stock price target on drug data
Leerink has increased its price target for Roivant Sciences (NASDAQ:ROIV) from $38 to $42, maintaining an Outperform rating, driven by data for IMVT-1402 in rheumatoid arthritis and its potential for $1.4 billion in risk-adjusted sales by 2035. The stock shows significant upside potential despite being considered overvalued by InvestingPro. Roivant Sciences also reported strong Q4 2026 earnings per share, exceeding expectations, though revenue fell short.
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives
Roivant Sciences (ROIV) reported a Q3 loss of US$265.9 million and a trailing 12-month net loss of US$809.24 million, with modest revenue of US$2.0 million for the quarter. Despite a large late-stage pipeline, analysts do not expect profitability for the next three years, contrasting with bullish long-term growth narratives. The company's shares trade at a P/B of 5.4x, significantly higher than peers, raising valuation concerns amidst ongoing losses.
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.68, Implies 30% Upside
Analysts have raised the average 12-month price target for Roivant Sciences Ltd. (ROIV) stock from $35.71 to $36.68, with projections ranging from $29.5 to $41 per share. This updated target suggests a potential upside of approximately 30% based on the May 19 closing price. The consensus rating from 13 analysts remains a "Buy," with 12 recommending a Buy and one a Hold.
Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed
Roivant and Immunovant have achieved success in treating rheumatoid arthritis (RA) with FcRn inhibition, a therapeutic approach where Johnson & Johnson previously faced setbacks. This marks the first RA win for FcRn inhibition, with patients showing significant improvements in tender and swollen joints. The article highlights Immunovant's drug IMVT-1402 and Roivant's strategic focus in this area.
Roivant Sciences Shares Rise 14% After Q4 Profit Boosted
Roivant Sciences (ROIV) shares rose 13.95% after the company reported a return to profitability in Q4 fiscal 2026. This financial improvement was primarily driven by a significant litigation settlement gain. Despite a decline in revenue, the biopharmaceutical company posted a net income of $303.0 million, or $0.28 per share, compared to a net loss in the prior year.
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin
TAT Technologies Ltd (NASDAQ: TATT) saw its shares rise significantly after reporting better-than-expected first-quarter financial results, with earnings of 26 cents per share and sales of $41.147 million, both surpassing analyst estimates. This report highlights several other large stocks that also experienced gains on Wednesday, including Immunovant Inc, Roivant Sciences Ltd, AMC Entertainment Holdings Inc, and Immunitybio Inc, driven by various company-specific news and analyst updates. The U.S. stock market, particularly the Nasdaq Composite, was higher during this session.
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q4 Revenue $2.5M, Vs. FactSet Est of $3.4M
Roivant Sciences Ltd. (ROIV) reported Q4 revenue of $2.5 million, falling short of the FactSet estimate of $3.4 million. This earnings flash provides key financial data for the pharmaceutical company.
Roivant gains after mid-stage trial data for Immunovant’s main asset
Roivant Sciences (ROIV) shares rose significantly after its subsidiary Immunovant (IMVT) released initial Phase 2 trial data for its lead asset, IMVT-1402. The drug is being evaluated for rheumatoid arthritis, an autoimmune disorder, and the positive results were based on Week 16 data.
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q4 Revenue $2.5M, vs. FactSet Est of $3.4M
Roivant Sciences Ltd. (ROIV) reported its Q4 revenue at $2.5 million, falling short of the FactSet estimate of $3.4 million. The biopharmaceutical company focuses on developing and commercializing medicines, with a pipeline including treatments for various autoimmune and pulmonary conditions. The article also provides recent stock performance and analyst consensus, alongside Company Profile and financial ratings.
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside
Eleven analysts have raised Roivant Sciences Ltd.'s average 12-month price target from $35.71 to $36.23, implying a potential upside of 28% from its May 19 closing price. The consensus rating for the stock remains a "Buy" across 13 analysts, with 12 recommending "Buy" and 1 recommending "Hold."
Roivant Sciences Q4 2026 earnings preview
This article is a placeholder for a preview of Roivant Sciences' Q4 2026 earnings. It does not contain any actual content about the earnings preview itself.
A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus
Roivant Sciences (ROIV) is gaining investor attention due to its IMVT-1402 program and upcoming Q4 2026 earnings report, despite recent short-term share price pressure. The company is considered 20% undervalued with a fair value of $35.67 per share, driven by its late-stage pipeline which could generate over $10 billion in peak sales. However, this valuation carries execution risks from clinical trials and ongoing litigation, and its P/B ratio is higher than industry averages, suggesting a richer outlook already priced in.
Roivant in the spotlight as earnings loom with approval ahead
Roivant Sciences Ltd. is set to announce its fiscal fourth-quarter and full-year results, with analysts expecting a loss of $0.29 per share and revenue of $3.76 million. The company is under scrutiny as it faces declining revenue but anticipates potential FDA approval for its lead drug, brepocitinib, by Q3 2026. Investors will be closely watching for updates on commercial strategy, the path to profitability, and pipeline progress, especially after a significant earnings and revenue miss in the previous quarter.
Book value per share of Roivant Sciences Ltd. – LSX:A3C4MS
The article focuses on the book value per share of Roivant Sciences Ltd. (LSX:A3C4MS), as presented on TradingView. It appears to be a financial data page with placeholders, indicating where specific period values, changes, and change percentages for the book value would be displayed. The content primarily lists various disclaimers and navigation options typical of a financial data platform.
Roivant Sciences Q4 2026 Earnings Preview — May 20, Street Expects -$0.35 EPS
Roivant Sciences is expected to report a Q4 2026 loss of $0.35 per share on revenue of $3.9 million, according to Wall Street analysts. The biotechnology company, which reports on May 20th, faces analyst caution with a widening consensus loss estimate. Investors will be looking for clinical milestone updates, new partnership announcements, and clarification on the cash runway, distinguishing operating performance from one-time gains.
Roivant Sciences Q4 2026 Earnings Preview — May 20, Street Expects -$0.35 EPS
Wall Street anticipates Roivant Sciences (ROIV) to report a Q4 2026 loss of $0.35 per share on revenues of $3.9 million. Analyst estimates for EPS range from -$0.49 to -$0.26, and revenue forecasts are between $0 and $7.0 million. The company's business model involves incubating biotech subsidiaries, with revenue primarily from royalties and milestone payments, and investors should focus on clinical milestones and capital allocation rather than short-term revenue fluctuations.
Earnings Preview: ROIV to Report Financial Results Pre-market on May 20
This article announces that Roivant Sciences Ltd. (ROIV) is scheduled to report its financial results pre-market on Monday, May 20. The company's earnings per share are expected to be $-0.28. Investors will be keenly watching the report for insights into the company's financial performance.
ROIV Q4'25 Earnings: revenue estimate is 3.41M USD
Roivant Sciences Ltd. (ROIV) is expected to announce its Q4'25 results on May 20, after the market closes. The company anticipates reporting revenue of 3.41 million USD and an EPS of (0.29) USD for the quarter. The article provides a table comparing reported and estimated revenue and EPS for several recent quarters, highlighting previous revenue and EPS surprises.
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Roivant (Nasdaq: ROIV) announced it will host a conference call and webcast on May 20, 2026, at 8:00 a.m. ET. The event will cover the company's financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update. Investors can register online to access the call.
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Roivant Sciences Ltd. (NASDAQ:ROIV) has received a "Moderate Buy" consensus recommendation from brokerages, with an average one-year price target of $30.55. Despite this positive outlook and several analysts raising their price targets, there has been notable insider selling of company shares totaling approximately $139.2 million last quarter. Roivant Sciences is a biopharmaceutical company that focuses on developing and commercializing innovative therapies through subsidiary businesses.
Insiders At Roivant Sciences Sold US$112m In Stock, Alluding To Potential Weakness
Insiders at Roivant Sciences have sold a significant amount of stock, totaling US$112 million over the past year. This large volume of selling, particularly by Executive Chairman Vivek Ramaswamy, suggests that insiders may believe the stock is overvalued or that future growth prospects are limited, despite a 40% stock price increase. The article highlights that companies with insider selling often underperform the market.
Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation Gap
The Baron Health Care Fund recently highlighted Roivant Sciences for the positive Phase 2 results of its drug brepocitinib in cutaneous sarcoidosis, suggesting the market might be undervaluing its potential. This endorsement draws attention to Roivant's pipeline beyond previous valuation discussions. The article emphasizes upcoming clinical milestones for brepocitinib and its potential impact on Roivant's broader portfolio and investor perception.
Baron Fund Puts Spotlight On Roivant’s Brepocitinib And Valuation Gap
The Baron Health Care Fund has recently highlighted Roivant Sciences (NasdaqGS:ROIV) due to positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, suggesting the market might be undervaluing the drug's potential. This endorsement draws attention to Roivant's pipeline beyond its current valuation or analyst coverage. Investors are now focused on future clinical milestones, regulatory interactions, and commercialization prospects for brepocitinib within Roivant's broader portfolio.
Assessing Roivant Sciences (ROIV) Valuation After Strong 1-Year Return And Recent Share Price Momentum
Roivant Sciences (ROIV) has seen significant momentum with a 158.0% 1-year return and a recent close at US$28.82, despite reporting a net loss of US$809.24 million. Analysts suggest the stock is undervalued, with a fair value of $35.67 per share, driven by a potential "$10 billion+ peak sales portfolio" from its late-stage pipeline. However, its high P/B ratio of 4.8x compared to industry averages raises questions about whether future success is already priced in.
Assessing Roivant Sciences (ROIV) Valuation After Strong 1-Year Return And Recent Share Price Momentum
Roivant Sciences (ROIV) has shown strong recent performance with a 158.0% 1-year return, yet it operates at a net loss. The company's valuation faces a dichotomy: a popular narrative suggests it is 19.2% undervalued with a fair value of $35.67 per share due to its late-stage pipeline and potential for significant future sales, but its P/B ratio of 4.8x indicates it could be richly valued compared to industry peers. Investors are encouraged to consider both the growth potential and significant clinical and financial risks before making an investment decision.
Assessing Roivant Sciences (ROIV) Valuation After Strong 1-Year Return And Recent Share Price Momentum
Roivant Sciences (ROIV) has seen significant share price momentum, with a 158.0% return over the past year, closing recently at US$28.82. Despite a net loss of US$809.24 million, its late-stage pipeline suggests a potential $10 billion+ peak sales portfolio, leading to an analyst-derived fair value of $35.67, indicating it might be undervalued. However, investors are cautioned to consider risks like clinical trial setbacks and legal outcomes, as well as the company's high P/B ratio compared to industry averages.
How New Analyst Coverage Spotlighting Brepocitinib’s Phase 3 Readouts At Roivant Sciences (ROIV) Has Changed Its Investment Story
New analyst coverage from Piper Sandler and Bernstein has brought Roivant Sciences' (ROIV) brepocitinib and its upcoming Phase 3 readouts for various immune-mediated diseases into sharp focus. This attention highlights brepocitinib's role as a key pillar in the company's inflammation and immunology pipeline, with positive Phase 3 VALOR data for dermatomyositis already announced. While the new coverage reinforces the investment thesis, investors are cautioned about potential risks of trial failures or modest efficacy.
Baron Health Care Fund Reports Roivant Sciences as Top Q1 2026 Performer
The Baron Health Care Fund reported Roivant Sciences (NASDAQ:ROIV) as its top Q1 2026 performer, despite the fund's overall underperformance during the quarter. Roivant's strategic drug development model, particularly its work on brepocitinib, was highlighted as a key driver of its strong stock performance, with shares gaining over 140% in the past year. The fund maintains a positive long-term outlook for the healthcare sector, focusing on innovative biopharmaceutical firms like Roivant.
(ROIV) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily analyzes Roivant Sciences Ltd. (NASDAQ: ROIV), highlighting strong near-term sentiment while predicting a mid-term neutrality moving towards a long-term positive bias. The AI-driven analysis identifies a mid-channel oscillation, an exceptional risk-reward short setup, and provides specific trading strategies including Position, Momentum Breakout, and Risk Hedging strategies with entry zones, targets, and stop losses. It also offers multi-timeframe signal analysis with support and resistance levels.
Roivant Sciences Ltd. (ROIV) Stock Analysis: A 28% Upside In Biotech Innovation
Roivant Sciences Ltd. (NASDAQ: ROIV) is a clinical-stage biopharmaceutical company with a robust market capitalization of $19.92 billion, currently priced at $27.83, and analysts project a 28.16% upside with an average target of $35.67. Despite financial metrics typical of research-heavy firms, including negative P/E and a focus on pipeline development, the company's long-term potential is strong due to innovative treatments for challenging diseases. Its lead programs and strategic pipeline, alongside positive analyst ratings, make it an attractive prospect for investors seeking growth in the healthcare sector.
How New Analyst Coverage Spotlighting Brepocitinib’s Phase 3 Readouts At Roivant Sciences (ROIV) Has Changed Its Investment Story
New analyst coverage from Piper Sandler and Bernstein has brought Roivant Sciences' brepocitinib and its upcoming Phase 3 readouts in multiple immune-mediated diseases into sharp focus. This attention highlights brepocitinib's potential to significantly reshape Roivant's investment narrative, with positive Phase 3 data for dermatomyositis already announced and an NDA filing planned for H1 2026. While the core investment thesis remains the same, investors are cautioned about potential clinical and execution risks, and the need to compare brepocitinib's efficacy against existing therapies.
Vanguard Group Inc. Has $912.68 Million Stock Position in Roivant Sciences Ltd. $ROIV
Vanguard Group Inc. increased its stake in Roivant Sciences Ltd. by 8.4% in the fourth quarter, reaching over $912 million. Despite significant insider selling totaling $139.2 million in the past 90 days, analysts maintain a "Moderate Buy" rating with an average target price of $30.55. The company currently trades near $27.83, with its stock price subject to analyst upgrades and downgrades.
Roivant Sciences Ltd. $ROIV Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 90.9% in the fourth quarter of the previous year, now holding 80,561 shares valued at approximately $1.75 million. Despite significant insider selling totaling $139.2 million over the last 90 days, institutional investors collectively own 64.76% of the company. Wall Street analysts maintain a "Moderate Buy" consensus rating for ROIV, with an average price target of $30.55, indicating potential upside from its recent opening price of $27.83.
Jennison Associates LLC Invests $51.07 Million in Roivant Sciences Ltd. $ROIV
Jennison Associates LLC has made a significant investment in Roivant Sciences Ltd. (NASDAQ:ROIV), purchasing 2,353,386 shares valued at approximately $51.07 million. This strategic move aligns with existing institutional interest, as firms like Vanguard Group Inc. and UBS Group AG also hold substantial stakes in the biopharmaceutical company. Despite some recent insider selling, analyst sentiment remains positive with a "Moderate Buy" rating and an average price target of $30.55.
Pictet Asset Management Holding SA Raises Holdings in Roivant Sciences Ltd. $ROIV
Pictet Asset Management Holding SA significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 790.3% in Q4, acquiring over 2 million additional shares. This move brings their total holdings to 2,312,436 shares, valued at approximately $50.18 million. Despite this institutional buying, insiders have been net sellers, offloading over 5 million shares in the last three months, including major sales by Frank Torti and CEO Eric Venker.
Piper Sandler and Bernstein Bullish on Roivant Sciences (ROIV)
Piper Sandler and Bernstein have issued bullish ratings on Roivant Sciences (ROIV), citing positive clinical data and potential multi-blockbuster opportunities for its drug brepocitinib. Piper Sandler set a $40 price target, highlighting expected approvals and study initiations, while Bernstein initiated coverage with a $35 price target, acknowledging risks but noting they are appropriately discounted. The company, an American biopharmaceutical firm, uses a unique "Vant" model to develop and commercialize medicines.
Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake
David Einhorn's Greenlight Capital has trimmed its stake in Roivant Sciences Ltd. (ROIV) after consistently holding it since Q1 2024. The firm's holding decreased by nearly 10% in Q4 2025 compared to Q3 2025 filings, even as Roivant recently settled a patent dispute with Moderna for $2.25 billion and released positive Phase 3 results for Batoclimab. Despite strong fundamentals and promising drug programs, the article suggests that some AI stocks may offer higher returns in a shorter timeframe.
UBS Group AG Grows Stock Holdings in Roivant Sciences Ltd. $ROIV
UBS Group AG significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 570% in Q4, acquiring an additional 15,645,836 shares to hold a total of 18,390,792 shares valued at $399.08 million. Despite this institutional growth, company insiders have been net sellers, disposing of approximately $139.2 million worth of shares. Analyst sentiment remains mixed but leaning positive, with a "Moderate Buy" consensus rating and an average price target of $30.55.
Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential
This article highlights Roivant Sciences Ltd. (NASDAQ:ROIV) as one of billionaire Joe Edelman’s top stock picks due to its huge upside potential. The company recently settled a major patent lawsuit with Moderna for $2.25 billion, boosting its cash reserves to over $4.5 billion, which is expected to fund its pipeline through 2028. Roivant also saw positive Phase 3 trial results for its drug Brepocitinib and completed a significant share repurchase program, making it an attractive investment for institutional investors.
Roivant Sciences (ROIV) Valuation Check After Recent Share Price Volatility
Roivant Sciences (ROIV) has seen recent share price volatility but shows strong long-term momentum. The stock is trading at US$27.41, significantly below the average analyst price target of $35.67, indicating it is undervalued. However, this relies on successful late-stage clinical trials and favorable legal outcomes, while its P/B ratio suggests the market might already be pricing in considerable future success.
Roivant Sciences (ROIV) Valuation Check After Recent Share Price Volatility
Roivant Sciences (ROIV) has experienced recent share price volatility but shows strong long-term momentum with a 1-year return of 148.96%. Despite trading at a perceived intrinsic discount and below analyst targets, the market might already be pricing in significant future success, as indicated by its P/B ratio compared to peers. Investors should consider both the potential for future growth from successful clinical trials and the risks associated with a high valuation.
Roivant Sciences (ROIV) Valuation Check After Recent Share Price Volatility
Roivant Sciences (ROIV) has experienced recent stock volatility, closing at US$27.41 with mixed short-term returns but strong longer-term momentum. Despite a popular narrative suggesting a fair value of $35.67, indicating it's undervalued, another perspective highlights its P/B ratio of 4.6x, significantly higher than peers, suggesting the market may already be pricing in considerable future success. Investors are advised to examine key rewards and warning signs, as well as potential risks like clinical setbacks or litigation costs.
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares
Roivant Sciences CEO Eric Venker sold 200,000 shares of the company's stock on April 20th for $5.918 million, reducing his stake by over 10%. This sale was part of a pre-arranged trading plan and follows similar sales in February and March. Analysts maintain a "Moderate Buy" rating for ROIV, with several firms raising their price targets for the stock.
Price-Driven Insight from (ROIV) for Rule-Based Strategy
This article provides a price-driven insight into Roivant Sciences Ltd. (NASDAQ: ROIV) for rule-based trading strategies. It highlights a near-term neutral sentiment amidst mid and long-term strength, with support being tested, and offers specific trading strategies (Position, Momentum Breakout, and Risk Hedging) with detailed entry, target, and stop-loss levels based on AI-generated signals. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Roivant Sciences(ROIV.US) Officer Sells US$5.92 Million in Common Stock
An officer of Roivant Sciences (ROIV.US), Venker Eric, sold 200,000 shares of common stock on April 20, 2026. The transaction was valued at approximately $5.92 million, with an average selling price of $29.59 per share. This transaction is considered an insider trade and is required to be reported under federal securities laws.
Roivant (NASDAQ: ROIV) president exercises 200K options, sells shares
Roivant Sciences Ltd.'s president and Immunovant CEO, Eric Venker, exercised stock options for 200,000 common shares at $3.85 per share and subsequently sold all 200,000 shares on the open market at a weighted average price of $29.59. Following these transactions, Venker directly holds 1,647,546 common shares, with an additional 4,644,834 stock options remaining. These transactions were filed as a Form 4, indicating an exercise-and-sale pattern.
